GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Freeline Therapeutics Holdings PLC (NAS:FRLN) » Definitions » 3-Year Revenue Growth Rate

Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) 3-Year Revenue Growth Rate : 0.00% (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Freeline Therapeutics Holdings 3-Year Revenue Growth Rate?

Freeline Therapeutics Holdings's Revenue per Share for the three months ended in Sep. 2023 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Competitive Comparison of Freeline Therapeutics Holdings's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Freeline Therapeutics Holdings's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Freeline Therapeutics Holdings's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Freeline Therapeutics Holdings's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Freeline Therapeutics Holdings's 3-Year Revenue Growth Rate falls into.



Freeline Therapeutics Holdings 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Freeline Therapeutics Holdings  (NAS:FRLN) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


Freeline Therapeutics Holdings 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Freeline Therapeutics Holdings's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
Gunnels Wood Road, Sycamore House, Stevenage, Hertfordshire, GBR, SG1 2BP
Freeline Therapeutics Holdings PLC is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its lead product candidates are FLT180a for the treatment of hemophilia B, FLT190 for the treatment of Fabry disease and FLT201 for the treatment of Gaucher disease Type 1.

Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Headlines